No Orkambi Deal Yet For England, But Vertex’ Portfolio Approach Still On The Table

07:59 EDT 27 Apr 2018 | Elsevier Business Intelligence

Dialogue between Vertex and NHS England over cystic fibrosis drug Orkambi are set to continue after productive talks on April...

More From BioPortfolio on "No Orkambi Deal Yet For England, But Vertex’ Portfolio Approach Still On The Table"